Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea

Hyungil Seo, Byong Duk Ye, Eun Mi Song, Sun Ho Lee, Kiju Chang, Ho Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong Hoon Yang, Kyung Jo Kim, Jeong Sik Byeon, Seung Jae Myung, Suk Kyun Yang

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Background and Aims: Large-scale studies regarding the long-term outcomes of adalimumab (ADA) treatment in Asian patients with Crohn’s disease (CD) are still scarce. Methods: We retrospectively analyzed the long-term outcomes of ADA treatment in Korean CD patients who commenced on scheduled ADA treatment at Asan Medical Center between November 2008 and July 2016. Clinical response was defined as maintaining ADA treatment without dose intensification (DI) and/or major abdominal surgery (MAS). Results: Of the 254 patients who received at least two doses of ADA at 2-week intervals as induction therapy, 250 patients (98.4%) showed an initial favorable response by week 4. Among responders, 243 patients were followed up for longer than 4 weeks and were included for further analysis. The median duration of ADA maintenance therapy was 19.4 months. At the last follow-up, 45 patients (18.5%) required DI after a median of 16.8 months and 31 (12.8%) required MAS after a median of 8.9 months. Finally, 161 patients (66.3%) were still receiving ADA without DI and/or MAS. The cumulative probability of maintaining ADA without DI and/or MAS was 81.1% at 1 year, and 36.5% at 5 years. Secondary loss of response to previous infliximab (P = 0.001) and elevated baseline C-reactive protein at starting ADA treatment (P = 0.008) were identified as independent predictors of a poor response to ADA treatment using multivariate regression analysis. Conclusions: The long-term outcome of ADA treatment in a real-life cohort of Korean patients with CD appears to be comparable to that reported in previously published Western studies.

Original languageEnglish
Pages (from-to)2882-2893
Number of pages12
JournalDigestive Diseases and Sciences
Issue number10
StatePublished - 1 Oct 2017

Bibliographical note

Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.


  • Adalimumab
  • Crohn disease
  • Korea
  • Treatment outcome


Dive into the research topics of 'Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea'. Together they form a unique fingerprint.

Cite this